### Learner Notification

**MED Learning Group**

**Checkpoint Inhibition Combinations in Melanoma: Evaluating Current Therapies and the Role of Anti-LAG3 Antibodies**

**February 13 – May 25, 2023
Online**

**Acknowledgement of Financial Commercial Support**

Regeneron Pharmaceuticals

**Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

**Satisfactory Completion**

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

**Joint Accreditation Statement**

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Nurses (ANCC) Credit Designation**

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

###### Objectives - After Attending This Program You Should Be Able To

1. Assess the relationship between checkpoint inhibition and immunopathology in melanoma.
2. Evaluate the latest clinical data with anti-LAG3 antibody combinations in advanced melanoma.
3. Summarize best practices for maximizing safety of adverse events with combination immunotherapy approaches in melanoma.

**Disclosure of Conflict of Interest**

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

|  |  |  |
| --- | --- | --- |
| **First Name** | **Last Name** | **Commercial Interest: Relationship** |
| Ana Maria | Albino | NA |
| Russie | Allen | NA |
| Vaidehee | Deshpande | NA |
| Jessica | Feygin | NA |
| Matthew | Frese | NA |
| Christina | Gallo | NA |
| David | Miller | Merck, EMD Serono, Regeneron, Sanofi Genzyme, Pfizer, Castle Biosciences, Avstera therapeutics, Checkpoint Therapeutics: Consultant; Regeneron, Kartos Therapeutics, NeoImmune Tech: Contracted Research; Checkpoint Therapeutics, Avstera Therapeutics: Stock Shareholder |
| Vishal | Patel | Regeneron, PhD Biosciences, Almirall: Consultant; Regeneron, Sanofi: Speakers Bureau; Science 37: Stock Shareholder |
| Jo | Shultz | NA |
| Lauren | Welch | NA |

Questions? Email Certificate@AmedcoEmail.com